Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis

Published:2020-11-14 Issue:1 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Singh Surjit¹^ORCID,Singh Saurabh²^ORCID,Thangaswamy Abisha¹,Thangaraju Pugazhenthan³^ORCID,Varthya Shoban Babu¹^ORCID

Affiliation:

1. Department of Pharmacology All India Institute of Medical Sciences Jodhpur India

2. Department of Dermatology, Venereology and Leprology All India Institute of Medical Sciences Jodhpur India

3. Department of Pharmacology All India Institute of Medical Sciences Raipur India

Funder

McMaster University

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14487

Reference26 articles.

2. Manifestations systémiques extracutanées du psoriasis pustuleux généralisé

3. Genetic Epidemiology of Psoriasis

4. Psoriasis Pathogenesis and Treatment

5. Critical role of environmental factors in the pathogenesis of psoriasis

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia;Cost Effectiveness and Resource Allocation;2023-12-09

2. Risankizumab for the treatment of genital psoriasis: A 1‐year, real‐world experience;Journal of the European Academy of Dermatology and Venereology;2023-10-17

3. Risankizumab versus apremilast in the era of skin clearance;British Journal of Dermatology;2023-09-06

4. Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis;Journal of Clinical Medicine;2023-08-20

5. Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database;Pharmaceutics;2023-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3